EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia

Anna Torrent, Josep Maria Ribera

Acta Haematologica · 2025-06-24 · 149 (1) · 24-38

DOI: 10.1159/000547026 ↗
AbstractBibliografische Angaben

Abstract

Background: Philadelphia chromosome-positive acute lymphoblastic leukemia has historically been associated with poor prognosis and limited therapeutic options. Over the past 2 decades, however, the treatment paradigm has markedly shifted. Summary: The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and ponatinib, has revolutionized frontline therapy, significantly improving remission rates and long-term survival. These agents, when combined with reduced-intensity chemotherapy or even with corticosteroids, have enabled less toxic regimens, particularly beneficial for older or unfit patients. The implementation of measurable residual disease monitoring has emerged as a pivotal tool for risk stratification and therapeutic decision-making. Consequently, the role of allogeneic hematopoietic stem cell transplantation, considered a cornerstone of curative treatment, is being reevaluated in patients achieving sustained deep molecular responses. More recently, immunotherapeutic strategies – including the bispecific T-cell engager blinatumomab and chimeric antigen receptor (CAR) T-cell therapies – have emerged as effective alternatives to conventional chemotherapy and TKIs. Key Messages: While TKIs remain the backbone of treatment, the integration of immunotherapeutic strategies – including bispecific antibodies and CAR T-cell therapy – has expanded therapeutic options, not only in the R/R setting but increasingly in frontline regimens. Ongoing research aimed at optimizing the sequencing, combination, and duration of these therapies is essential to further enhance clinical outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →